Auto-immunity Programs

About Laigo Bio

Laigo Bio is an early-stage biotech developing a novel targeted protein degradation platform called SureTACs (Surface Removal Targeting Chimeras). The technology uses bispecific antibodies to bring disease-causing membrane proteins into proximity with specific E3 ligases, marking them for lysosomal destruction. The company has raised €17 million in seed financing to advance its preclinical oncology and auto-immunity programs and is exploring strategic partnerships. Laigo's approach aims to tackle traditionally 'undruggable' targets with high tissue specificity.

Therapeutic Areas